

Xiaoyan Si

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8576029/xiaoyan-si-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43 papers	268 citations	9 h-index	14 g-index
58 ext. papers	390 ext. citations	2.7 avg, IF	3.51 L-index

#	Paper	IF	Citations
43	Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis.. <i>Thoracic Cancer</i> , 2022 ,	3.2	1
42	Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report. <i>Thoracic Cancer</i> , 2021 , 12, 1244-1247	3.2	4
41	Immune checkpoint inhibitor-related epidermal necrolysis: A rare condition with poor prognosis. <i>European Journal of Cancer</i> , 2021 , 145, 194-196	7.5	3
40	Myocarditis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e14579-e14579	2.2	
39	Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. <i>Cancer Medicine</i> , 2021 , 10, 188-198	4.8	6
38	Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021 , 12, 357-363	3.2	5
37	Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period.. <i>Thoracic Cancer</i> , 2021 ,	3.2	1
36	A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920965849	5.4	2
35	Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study. <i>Thoracic Cancer</i> , 2020 , 11, 1869-1875	3.2	1
34	Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum-pemetrexed: The first report of two cases. <i>Thoracic Cancer</i> , 2020 , 11, 2339-2342	3.2	2
33	Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 1216-1223	3.2	4
32	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. <i>Thoracic Cancer</i> , 2020 , 11, 829-834	3.2	3
31	Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 799-804	3.2	13
30	Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. <i>Thoracic Cancer</i> , 2020 , 11, 810-818	3.2	11
29	Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction. <i>Thoracic Cancer</i> , 2020 , 11, 1099-1104	3.2	2
28	Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. <i>Thoracic Cancer</i> , 2020 , 11, 805-809	3.2	3
27	Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. <i>Thoracic Cancer</i> , 2020 , 11, 594-602	3.2	9

26	Management of immune checkpoint inhibitor-related adverse events: A review of case reports. <i>Thoracic Cancer</i> , 2020 , 11, 498-504	3.2	6
25	Histologic transformation of lung cancer during pembrolizumab therapy: A case report. <i>Thoracic Cancer</i> , 2020 , 11, 793-796	3.2	4
24	Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 1746-1751	3.2	6
23	Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2020 , 11, 1647-1654	3.2	9
22	Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients. <i>Thoracic Cancer</i> , 2020 , 11, 1621-1632	3.2	18
21	Management of immune checkpoint inhibitor-related dermatologic adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 488-492	3.2	6
20	Management of immune checkpoint inhibitor-related rheumatic adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 198-202	3.2	1
19	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. <i>Thoracic Cancer</i> , 2020 , 11, 191-197	3.2	26
18	Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. <i>Thoracic Cancer</i> , 2020 , 11, 475-480	3.2	3
17	Use of glucocorticoids in the management of immunotherapy-related adverse effects. <i>Thoracic Cancer</i> , 2020 , 11, 3047-3052	3.2	6
16	NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score. <i>Cancer Management and Research</i> , 2020 , 12, 5975-5985	3.6	3
15	Pulmonary and Skeletal Infection of. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 1169-1170	10.2	
14	Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor-associated adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 2077-2086	3.2	0
13	Opportunistic infections complicating immunotherapy for non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 1689-1694	3.2	4
12	Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. <i>Thoracic Cancer</i> , 2019 , 10, 551-556	3.2	25
11	EGFR T790M detection in formalin-fixed paraffin-embedded tissues of patients with lung cancer using RNA-based in situ hybridization: A preliminary feasibility study. <i>Thoracic Cancer</i> , 2019 , 10, 1936-1944	3.2	5
10	Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease. <i>OncoTargets and Therapy</i> , 2019 , 12, 5545-5549	4.4	3
9	Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation. <i>Lung Cancer</i> , 2018 , 122, 1-6	5.9	13

8	Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2018 , 9, 1056-1061	3.2	5
7	Rebiopsy status among non-small cell lung cancer patients after Icotinib therapy in China.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21146-e21146	2.2	
6	Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy. <i>OncoTargets and Therapy</i> , 2018 , 11, 7513-7519	4.4	4
5	Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. <i>Lung Cancer</i> , 2018 , 125, 142-149	5.9	16
4	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018 , 122, 32-37	5.9	27
3	The ability of avitinib to penetrate the blood brain barrier and its control of intra-/extra- cranial disease in patients of non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20613-e20613	2.2	5
2	The role of epidermal growth factor receptor mutations (EGFRm) in NSCLC with leptomeningeal metastasis: A prospective observational study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e19070-e19070	2.2	
1	Safety and efficacy of cetuximab combined with chemotherapy in Chinese patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2012 , 3, 188-193	3.2	